China Drug Regulation Updates 2026
China Drug Regulation Updates 2026 – Strategic Implications for International Biopharma and MedTech China has recently updated the implementing regulations under its Drug Administration Law. The changes reflect a continued shift toward encouraging pharmaceutical innovation while strengthening regulatory oversight across the full product lifecycle. On January 27, 2026, the State Council promulgated the revised “Regulations for the…
Navigating the Hong Kong Medicines Regulatory System
The Year of the Dragon stands as a fitting emblem for Hong Kong’s medicines regulatory system, symbolising strength, resilience, and vigilant oversight
The Adjutor Healthcare Group Expands Global Presence with the Establishment of Adjutor Healthcare Hong Kong
Today marks a significant milestone for the Adjutor Healthcare Group, as we proudly announce the establishment of Adjutor Healthcare Hong Kong, further solidifying our commitment to excellence supporting global healthcare, development, regulatory and commercialisation needs.
Disclaimer:
The information provided is intended for general informational purposes only and does not constitute legal, professional, or any other type of advice. While every effort has been made to ensure the accuracy and reliability of the information, the authors make no representations or warranties, express or implied, regarding the completeness, suitability, or applicability of the content to specific products or situations.